Display options
Cite
Syed YA, Patel-Yadav AK, Rivers C, et al. Stereotactic radiotherapy for prostate cancer: A review and future directions. World J Clin Oncol. 2017;8(5):389-397doi: 10.5306/wjco.v8.i5.389.
Syed, Y. A., Patel-Yadav, A. K., Rivers, C., & Singh, A. K. (2017). Stereotactic radiotherapy for prostate cancer: A review and future directions. World journal of clinical oncology, 8(5), 389-397. https://doi.org/10.5306/wjco.v8.i5.389
Syed, Yusef A, et al. "Stereotactic radiotherapy for prostate cancer: A review and future directions." World journal of clinical oncology vol. 8,5 (2017): 389-397. doi: https://doi.org/10.5306/wjco.v8.i5.389
Syed YA, Patel-Yadav AK, Rivers C, Singh AK. Stereotactic radiotherapy for prostate cancer: A review and future directions. World J Clin Oncol. 2017 Oct 10;8(5):389-397. doi: 10.5306/wjco.v8.i5.389. PMID: 29067275; PMCID: PMC5638714.
Copy Download .nbib Format: NLM
Share it on

World J Clin Oncol. 2017 Oct 10;8(5):389-397. doi: 10.5306/wjco.v8.i5.389.

Stereotactic radiotherapy for prostate cancer: A review and future directions.

World journal of clinical oncology

Yusef A Syed, Ami K Patel-Yadav, Charlotte Rivers, Anurag K Singh

Affiliations

  1. Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30342, United States.
  2. Department of Radiation Oncology, University at Buffalo, Buffalo, NY 14263, United States.
  3. Department of Radiation Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, United States.

PMID: 29067275 PMCID: PMC5638714 DOI: 10.5306/wjco.v8.i5.389

Abstract

Prostate cancer affects over 200000 men annually in the United States alone. The role of conventionally fractionated external beam radiation therapy (RT) is well established as a treatment option for eligible prostate cancer patients; however, the use of stereotactic body radiotherapy (SBRT) in this setting is less well defined. Within the past decade, there have been a number of studies investigating the feasibility of SBRT as a potential treatment option for prostate cancer patients. SBRT has been well studied in other disease sites, and the shortened treatment course would allow for greater convenience for patients. There may also be implications for toxicity as well as disease control. In this review we present a number of prospective and retrospective trials of SBRT in the treatment of prostate cancer. We focus on factors such as biochemical progression-free survival, prostate specific antigen (PSA) response, and toxicity in order to compare SBRT to established treatment modalities. We also discuss future steps that the clinical community can take to further explore this new treatment approach. We conclude that initial studies examining the use of SBRT in the treatment of prostate cancer have demonstrated impressive rates of biochemical recurrence-free survival and PSA response, while maintaining a relatively favorable acute toxicity profile, though long-term follow-up is needed.

Keywords: Hypofractionation; Prostate cancer; Radiation therapy; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; Toxicity

Conflict of interest statement

Conflict-of-interest statement: There are no conflicts of interest for any of the above listed authors.

References

  1. Front Oncol. 2014 May 26;4:122 - PubMed
  2. Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):25-33 - PubMed
  3. Eur J Cancer. 2016 May;59:142-151 - PubMed
  4. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1463-8 - PubMed
  5. Eur Urol. 2011 Dec;60(6):1133-9 - PubMed
  6. J Clin Oncol. 2011 May 20;29(15):2020-6 - PubMed
  7. Cancer. 2016 Jul 15;122(14 ):2234-41 - PubMed
  8. Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1099-105 - PubMed
  9. Radiat Oncol. 2016 Jan 21;11:8 - PubMed
  10. J Clin Oncol. 2010 Mar 1;28(7):1106-11 - PubMed
  11. BMC Urol. 2013 Oct 17;13:49 - PubMed
  12. Radiat Oncol. 2013 Mar 13;8:58 - PubMed
  13. Radiat Oncol. 2014 Jun 26;9:148 - PubMed
  14. Front Oncol. 2014 Nov 14;4:279 - PubMed
  15. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82 - PubMed
  16. Cancer. 2012 Aug 1;118(15):3681-90 - PubMed
  17. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74 - PubMed
  18. N Engl J Med. 2016 Oct 13;375(15):1415-1424 - PubMed
  19. Front Oncol. 2014 Oct 28;4:301 - PubMed
  20. Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1588-97 - PubMed
  21. BMC Urol. 2010 Feb 01;10:1 - PubMed
  22. J Radiat Oncol. 2013 Mar;2(1):63-70 - PubMed
  23. Cancer. 2013 Sep 15;119(18):3265-71 - PubMed
  24. Radiother Oncol. 2013 Nov;109(2):217-21 - PubMed
  25. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  26. Brachytherapy. 2012 Jan-Feb;11(1):20-32 - PubMed
  27. Radiat Oncol. 2011 Jan 10;6:3 - PubMed
  28. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):915-28 - PubMed
  29. Urology. 1990 Aug;36(2):107-11 - PubMed
  30. Cureus. 2015 Dec 04;7(12):e395 - PubMed
  31. JAMA. 2005 Sep 14;294(10):1233-9 - PubMed
  32. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):228-34 - PubMed
  33. Radiat Oncol. 2014 Nov 15;9:241 - PubMed

Publication Types